Dyne Immune

Dyne Immune is a pre-clinical stage biotechnology company focused on developing a new class of selective immunotherapies for autoimmune and inflammatory diseases. The company utilizes a proprietary platform technology designed to deliver therapeutic payloads directly to specific subsets of immune cells, allowing for precise modulation of the immune system. By targeting only the cells driving disease pathogenesis, Dyne Immune aims to achieve superior efficacy while avoiding the systemic side effects and broad immunosuppression associated with conventional treatments. Founded by the creator of Dyne Therapeutics, the company is building a robust pipeline of targeted biologics to address significant unmet needs in chronic immunological conditions.